Evidence-Informed Update of Argentina's Health Benefit Package: Application of a Rapid Review Methodology.

Decision making Health benefit package Resource allocation Technology assessment health

Journal

International journal of technology assessment in health care
ISSN: 1471-6348
Titre abrégé: Int J Technol Assess Health Care
Pays: England
ID NLM: 8508113

Informations de publication

Date de publication:
11 Mar 2022
Historique:
entrez: 11 3 2022
pubmed: 12 3 2022
medline: 15 3 2022
Statut: epublish

Résumé

Argentina has a fragmented healthcare system with social security covering almost two thirds of the population. Its benefit package-called compulsory medical program (PMO; by its Spanish acronym Programa Médico Obligatorio)-has not been formally and widely updated since 2005. However, laws, clinical practice guidelines (CPGs), and a high-cost technology reimbursement fund complement it. Our objective was to comprehensively review such a PMO and propose an update considering the corresponding complementary sources. We followed four steps: (i) identification of health technologies from the current PMO and complementary sources, (ii) prioritization, (iii) assessment through rapid health technology assessment (HTA), and (iv) appraisal and recommendations. We evaluated three value domains: quality of evidence, net benefit, and economics, which were summarized in a five-category recommendation traffic-light scale ranging from a strong recommendation in favor of inclusion to a strong recommendation for exclusion. Eight hundred fifty technologies were identified; 164 of those, considered as high priority, were assessed through rapid HTAs. Those technologies mentioned in laws and CPGs were mostly outpatient essential medicines, whereas those from the reimbursement system were mostly high-cost drugs; of these 101 technologies, 50 percent were recommended to be kept in the PMO. The other 63 (identified by the Superintendence of Health Services, technology producers, and patients) were mostly medical procedures and high-cost drugs; only 25 percent of those resulted in a favorable recommendation. A methodology based on four clearly identified steps was used to carry out a comprehensive review of an outdated and fragmented benefit package. The use of rapid HTAs and a traffic-light recommendation framework facilitated the deliberative evidence-based update.

Identifiants

pubmed: 35274604
doi: 10.1017/S0266462322000034
pii: S0266462322000034
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24

Subventions

Organisme : Superintendence of Health Services, Ministry of Health, Argentina

Auteurs

Andrea Alcaraz (A)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Verónica Alfie (V)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Lucas Gonzalez (L)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Sacha Virgilio (S)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Sebastián Garcia-Marti (S)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Federico Augustovski (F)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Andrés Pichon-Riviere (A)

Department of Health Technology Assessment and Economic Evaluation Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH